New hope for lung cancer patients too weak for standard treatment?
NCT ID NCT04221529
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin and etoposide) is safe and effective for people with extensive-stage small cell lung cancer who have poor performance status (ECOG 2). The trial enrolled 70 participants and measured overall survival and tumor response. The goal is to see if this combination can help a group of patients who often have very limited treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC,EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asklepios Klinik Altona
Hamburg, 22763, Germany
-
Brüderkrankenhaus St. Josef
Paderborn, 33098, Germany
-
Fachkliniken Wangen
Wangen, 88239, Germany
-
Helios Dr. Horst Schmidt Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Helios Universitätsklinikum
Wuppertal, 42283, Germany
-
Johannes Wesling Klinikum
Minden, 32429, Germany
-
Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie c/o Wilhelminenspital der Stadt Wien
Vienna, 1160, Austria
-
Klinikum Esslingen GmbH
Esslingen am Neckar, 73730, Germany
-
Klinikum Klagenfurt
Klagenfurt, 9020, Austria
-
Klinikum Löwenstein gGmbH
Löwenstein, 74245, Germany
-
Klinikum der Universität München
München, 80336, Germany
-
Krankenhaus Martha-Maria Halle-Dölau
Halle, 06120, Germany
-
LungenClinic Grosshansdorf GmbH
Großhansdorf, 22927, Germany
-
Niels-Stensen-Kliniken
Georgsmarienhütte, 49124, Germany
-
St. Josef Hospital
Bochum, 44791, Germany
-
Universität Heidelberg
Heidelberg, 69126, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79106, Germany
-
Universitätsklinikum Gießen und Marburg GmbH
Marburg, 35043, Germany
-
Universitätsklinikum Krems
Krems, 3500, Austria
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (an immunotherapy drug) plus carboplatin and etoposide (chemotherapy)
What this could lead to
If successful, this could show that adding immunotherapy to standard chemo is safe and effective for SCLC patients who are too weak for standard treatment, potentially improving survival in this group.
What could go wrong
This is a small, single-arm phase 2 trial with only 70 participants, so results may not be definitive. Patients with poor performance status often have worse outcomes, and the added immunotherapy may not improve survival or could cause additional side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.